Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
Israeli Strikes Kill Six in Gaza as Ceasefire Talks Continue in Cairo 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Israel Sets October 27 Election as Netanyahu Faces Tough Political Test 
Iraq PM Visits Washington as U.S. Oil, Gas Deals Take Center Stage 
Venezuela Appoints Felix Plasencia to Lead Foreign Relations and Trade 
Iran Says It Closes Strait of Hormuz After Warning Shot at Vessel 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Trump Signs Memorandum Backing Americans’ Right to Repair Their Own Vehicles 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Brazil to Phase Out Gasoline Subsidy First as Diesel Support Stays Longer 
EU to Propose New Rules Limiting Children's Access to Social Media 
U.S. Health Secretary Robert F. Kennedy Jr. told lawmakers this week that he is open to sharing details about David Geier’s contract with the Department of Health and Human Services (HHS), signaling growing scrutiny over the controversial appointment. During a Senate Finance Committee hearing, Kennedy stated that the contract could be provided to senators before the end of the week, offering what may become the first clear explanation of Geier’s responsibilities within the agency.
David Geier, known for his long-standing anti-vaccine activism, is currently working as a contractor tied to the Centers for Disease Control and Prevention (CDC). According to federal records, he is listed as a senior data analyst within the HHS system. His involvement has raised concerns among lawmakers and public health experts, particularly given his history of promoting debunked claims linking vaccines to autism.
Senator Ben Ray Luján of New Mexico pressed Kennedy on whether the administration would also release the protocols guiding Geier’s work. Kennedy responded that such protocols are not yet in place but promised they would be shared once the vaccine safety review is completed. Kennedy has previously indicated that Geier is leading a review of CDC vaccine data, a move that has sparked debate due to Geier’s controversial background.
Geier’s past actions have added to the concern. He was previously fined in Maryland for practicing medicine without a license and for administering unsafe treatments to children with autism. Critics argue that his involvement in federal health initiatives could undermine public trust in vaccine safety.
The situation highlights ongoing tensions around vaccine policy, public health transparency, and the role of individuals with disputed scientific views in government positions. As pressure builds, the release of Geier’s HHS contract could play a key role in shaping public and political response to the administration’s handling of vaccine-related issues.
